A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2480-2488

  Doyle, Patricia S ^a   Chen, Chiung Kuang ^a   Johnston, Jonathan B ^a   Hopkins, Stephanie D ^a   Leung, Siegfried S F ^a   Jacobson, Matthew P ^a   Engel, Juan C ^a   McKerrow, James H ^a   Podust, Larissa M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; LP10; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; STEROL; STEROL 14ALPHA DEMETHYLASE; STEROL 14ALPHA DEMETHYLASE INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CHAGAS DISEASE; CONTROLLED STUDY; DEMETHYLATION; DRUG MECHANISM; ELECTRON MICROSCOPE; FEMALE; HISTOPATHOLOGY; MASS FRAGMENTOGRAPHY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

AMINOPYRIDINES; ANIMALS; ANTIPROTOZOAL AGENTS; CATALYTIC DOMAIN; CHAGAS DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MICE; MICE, INBRED C3H; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, MOLECULAR; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; STEROLS; TRYPANOSOMA CRUZI;

EID: 77952622536     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00281-10     Document Type: Article

References (48)

1. Avila, H. A., J. B. Pereira, O. Thiemann, E. De Paiva, W. DeGrave, C. M. Morel, and L. Simpson. 1993. Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. J. Clin. Microbiol. 31:2421-2426.
2. Buckner, F. 2008. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections, p. 61-80. In H. K. Majumder (ed.), Drug targets in kinetoplastid parasites, vol.625. Springer, New York, NY.
3. Buckner, F. S., B. M. Joubert, S. M. Boyle, R. T. Eastman, C. L. Verlinde, and S. P. Matsuda. 2003. Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol. Biochem. Parasitol. 132:75-81.
4. Buckner, F. S., A. J. Wilson, T. C. White, and W. C. Van Voorhis. 1998. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. 42:3245-3250.
5. Cazzulo, J. J., B. M. Franke de Cazzulo, J. C. Engel, and J. J. Cannata. 1985. End products and enzyme levels of aerobic glucose fermentation in trypanosomatids. Mol. Biochem. Parasitol. 16:329-343.
6. Chagas, C. 1909. Nova trypanosomiase humana. Gac. Med. Bahia 40:433-440.
7. Chau, A. S., C. A. Mendrick, F. J. Sabatelli, D. Loebenberg, and P. M. McNicholas. 2004. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob. Agents Chemother. 48:2124-2131.
8. Chen, C.-K., P. S. Doyle, L. V. Yermalitskaya, Z. B. Mackey, K. K. H. Ang, J. H. McKerrow, and L. M. Podust. 2009. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Negl. Trop. Dis. 3:e372.
9. Chen, C.-K., S. S. F. Leung, C. Guilbert, M. P. Jacobson, J. H. McKerrow, and L. M. Podust. 2010. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl. Trop. Dis. 4:e651.
10. Chen, J., H. Li, R. Li, D. Bu, and Z. Wan. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37.
11. Croft, S. L., M. P. Barrett, and J. A. Urbina. 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 21:508-512.
12. da Silva Ferreira, M. E., J. L. Capellaro, E. dos Reis Marques, I. Malavazi, D. Perlin, S. Park, J. B. Anderson, A. L. Colombo, B. A. Arthington-Skaggs, M. H. Goldman, and G. H. Goldman. 2004. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob. Agents Chemother. 48:4405-4413.
13. Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez- Tudela. 2003. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
14. Doyle, P. S., M. Sajid, T. O'Brien, K. Dubois, J. C. Engel, Z. B. Mackey, and S. Reed. 2008. Drugs targeting parasite lysosomes. Curr. Pharm. Des. 14:889-900.
15. Doyle, P. S., Y. M. Zhou, J. C. Engel, and J. H. McKerrow. 2007. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob. Agents Chemother. 51:3932-3939.
16. Engel, J. C., P. S. Doyle, I. Hsieh, and J. H. McKerrow. 1998. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188:725-734.
17. Engel, J. C., B. M. Franke de Cazzulo, A. O. Stoppani, J. J. Cannata, and J. J. Cazzulo. 1987. Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimastigotes. Mol. Biochem. Parasitol. 26:1-10.
18. Ferraz, M. L., R. T. Gazzinelli, R. O. Alves, J. A. Urbina, and A. J. Romanha. 2007. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob. Agents Chemother. 51:1359-1364.
19. Fischer, R., J. Trzaskos, R. Magolda, S. Ko, C. Brosz, and B. Larsen. 1991. Lanosterol 14 alpha-methyl demethylase. Isolation and characterization of the third metabolically generated oxidative demethylation intermediate. J. Biol. Chem. 266:6124-6132.
20. Fischer, R. T., S. H. Stam, P. R. Johnson, S. S. Ko, R. L. Magolda, J. L. Gaylor, and J. M. Trzaskos. 1989. Mechanistic studies of lanosterol 14 alpha-methyl demethylase: substrate requirements for the component reactions catalyzed by a single cytochrome P-450 isozyme. J. Lipid Res. 30:1621-1632.
21. Friesner, R. A., J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, and P. S. Shenkin. 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47:1739-1749.
22. Friesner, R. A., R. B. Murphy, M. P. Repasky, L. L. Frye, J. R. Greenwood, T. A. Halgren, P. C. Sanschagrin, and D. T. Mainz. 2006. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49:6177-6196.
23. Howard, S. J., D. Cerar, M. J. Anderson, A. Albarrag, M. C. Fisher, A. C. Pasqualotto, M. Laverdiere, M. C. Arendrup, D. S. Perlin, and D. W. Denning. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
24. Hucke, O., M. H. Gelb, C. L. Verlinde, and F. S. Buckner. 2005. The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J. Med. Chem. 48:5415-5418.
25. Li, X., N. Brown, A. S. Chau, J. L. Lopez-Ribot, M. T. Ruesga, G. Quindos, C. A. Mendrick, R. S. Hare, D. Loebenberg, B. DiDomenico, and P. M. McNicholas. 2004. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J. Antimicrob. Chemother. 53:74-80.
26. Liendo, A., G. Visbal, M. M. Piras, R. Piras, and J. A. Urbina. 1999. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol. Biochem. Parasitol. 104:81-91.
27. Mann, P. A., R. M. Parmegiani, S. Q. Wei, C. A. Mendrick, X. Li, D. Loebenberg, B. DiDomenico, R. S. Hare, S. S. Walker, and P. M. McNicholas. 2003. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob. Agents Chemother. 47:577-581.
28. McCabe, R. 1988. Failure of ketoconazole to cure chronic murine Chagas' disease. J. Infect. Dis. 158:1408-1409.
29. McKerrow, J. H., P. J. Rosenthal, R. Swenerton, and P. Doyle. 2008. Development of protease inhibitors for protozoan infections. Curr. Opin. Infect. Dis. 21:668-672.
30. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2004. Substitutions at methionine 220 in the 14alpha- sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750.
31. Morris, M. I. 2009. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am. J. Health Syst. Pharm. 66:225-236.
32. Nascimento, A. M., G. H. Goldman, S. Park, S. A. Marras, G. Delmas, U. Oza, K. Lolans, M. N. Dudley, P. A. Mann, and D. S. Perlin. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47:1719-1726.
33. Pfaller, M. A., D. J. Diekema, M. A. Ghannoum, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, A. Espinel-Ingroff, C. L. Fowler, E. M. Johnson, C. C. Knapp, M. R. Motyl, L. Ostrosky-Zeichner, D. J. Sheehan, and T. J. Walsh. 2009. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
34. Pinazo, M.-J., G. Espinosa, M. Gállego, P. L. López- Chejade, J. Urbina, and J. Gascón. 2010. Treatment with posaconazole of a patient with systemic lupus erythematosus and Chagas disease. Am. J. Trop. Med. Hyg. 82:583-587.
35. Pinto e Silva, A. T., S. Costa-de-Oliveira, A. Silva-Dias, C. Pina-Vaz, and A. G. Rodrigues. 2009. Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles. FEMS Yeast Res. 9:626-633.
36. Podust, L. M., J. P. von Kries, A. Nasser Eddine, Y. Kim, L. V. Yermalitskaya, R. Kuehne, H. Ouellet, T. Warrier, M. Altekoster, J.-S. Lee, J. Rademann, H. Oschkinat, S. H. E. Kaufmann, and M. R. Waterman. 2007. Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob. Agents Chemother. 51:3915-3923.
37. Punukollu, G., R. M. Gowda, I. A. Khan, V. S. Navarro, and B. C. Vasavada. 2007. Clinical aspects of the Chagas' heart disease. Int. J. Cardiol. 115:279-283.
38. Roberts, C. W., R. McLeod, D. W. Rice, M. Ginger, M. L. Chance, and L. J. Goad. 2003. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126:129-142.
39. Rodriguez-Tudela, J. L., L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, A. Monzon, and M. Cuenca-Estrella. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472.
40. Sherman, W., T. Day, M. P. Jacobson, R. A. Friesner, and R. Farid. 2006. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49:534-553.
41. Taton, M., and A. Rahier. 1991. Properties and structural requirements for substrate specificity of cytochrome P-450-dependent obtusifoliol 14alpha-demethylase from maize (Zea mays) seedlings. Biochem. J. 277:483-492.
42. Teixeira, A. R., N. Nitz, M. C. Guimaro, C. Gomes, and C. A. Santos-Buch. 2006. Chagas disease. Postgrad. Med. J. 82:788-798.
43. Urbina, J. A., G. Payares, L. M. Contreras, A. Liendo, C. Sanoja, J. Molina, M. Piras, R. Piras, N. Perez, P. Wincker, and D. Loebenberg. 1998. Anti-proliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. 42:1771-1777.
44. Urbina, J. A., G. Payares, J. Molina, C. Sanoja, A. Liendo, K. Lazardi, M. M. Piras, R. Piras, N. Perez, P. Wincker, and J. F. Ryley. 1996. Cure of short- and long-term experimental Chagas' disease using D0870. Science 273:969-971.
45. Urbina, J. A., G. Payares, C. Sanoja, J. Molina, R. Lira, Z. Brener, and A. J. Romanha. 2003. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents 21:39-48.
46. Xiao, L., V. Madison, A. S. Chau, D. Loebenberg, R. E. Palermo, and P. M. McNicholas. 2004. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574.
47. Zhu, K., M. R. Shirts, R. A. Friesner, and M. P. Jacobson. 2007. Multiscale optimization of a truncated Newton minimization algorithm and application to proteins and protein-ligand complexes. J. Chem. Theory Comput. 3:640-648.
48. Zonios, D. I., and J. E. Bennett. 2008. Update on azole antifungals. Semin. Respir. Crit. Care Med. 29:198-210.